**Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr−/− Mice**

Holly E. Bates, Jonathan E. Campbell, John R. Usher, Laurie L. Baggio, Adriano Maida, Yutaka Seino, and Daniel J. Drucker

Glucose-dependent insulinotropic polypeptide (GIP) promotes glucose-dependent insulin secretion. However, GIP also enhances glucocorticoid secretion and promotes adiposity. Because obesity and diabetes are glucocorticoid dependent, we examined whether the effects of GIP on energy balance and glycemia are regulated by glucocorticoids using pharmacological activation of GIP receptor (GIPR) signaling with [D-Ala²]GIP in mice and in Y1 adrenocortical cells. Genetic elimination of GIPR activity was also studied in normal- and high fat (HF)-fed Gipr−/− mice. [D-Ala²]GIP increased murine corticosterone levels in a GIPR-dependent manner. Conversely, basal corticosterone levels were reduced, whereas food deprivation resulted in significantly enhanced plasma corticosterone levels in Gipr−/− mice. [D-Ala²]GIP increased cAMP levels, activated ERK1/2, increased expression of steroidogenic genes, and increased neutral lipid storage in Y1GIPR cells. Gipr−/− adrenal glands demonstrated a twofold upregulation of the ACTH receptor mRNA and increased sensitivity to ACTH ex vivo. Although HF-fed Gipr−/− mice exhibited significantly lower plasma corticosterone, glucocorticoid-treated HF-fed Gipr−/− mice had similar energy balance and glycemia compared with Gipr+/+ controls. Hence, although the Gipr is essential for adrenal steroidogenesis and links HF feeding to increased levels of corticosterone, reduced glucocorticoid levels do not significantly contribute to the enhanced metabolic phenotypes in HF-fed Gipr−/− mice.

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide hormone released from intestinal K cells upon nutrient ingestion (1). The original description of GIP bioactivity encompassing inhibition of gastric emptying was subsequently expanded to include potentiation of glucose-dependent insulin secretion. GIP also can stimulate lipogenesis (2,3) and increase the activity of lipoprotein lipase in adipocytes in part through stimulatory effects on resistin secretion (4,5), thus enhancing fatty acid incorporation into adipose tissue.

Complementary insights into the physiological importance of endogenous GIP action have been obtained from studies using antagonists, elimination of GIP-producing K cells, or receptor knockout mice. Reduction or elimination of GIP action promotes resistance to genetic and high fat (HF) diet–induced obesity, increased energy expenditure and activity, reduced fat deposition in nonadipose and adipose depots, improved insulin sensitivity, and lower plasma resistin levels (5–9). Therefore, it remains unclear whether enhancement or reduction of GIP action is the preferred therapeutic strategy for the treatment of obesity-associated type 2 diabetes.

An additional extrapancreatic locus of GIP action is the adrenal cortex. Expression of the GIP receptor (GIPR) has been demonstrated in the adrenal cortex by radioligand binding (10) and RT-PCR (11) in rodents; however, the GIPR is not expressed in normal human adrenal glands (12). Ectopic expression of the GIPR in the human adrenal gland causes significant hypercortisolemia after meal ingestion and leads to Cushings syndrome (13), demonstrating that human GIPR activation is capable of robustly activating adrenal glucocorticoid secretion. Indeed, GIP administration increases corticosterone levels in rats (10), and isolated rat adrenocortical zona fasciculata/reticularis cells respond to GIP in a cAMP-dependent protein kinase manner (10). However, the mechanisms through which GIP stimulates glucocorticoid secretion and the physiological importance of adrenal GIP action remains poorly understood.

Chronic elevations of glucocorticoid levels promote obesity and/or metabolic syndrome, and many rodent models of obesity or insulin resistance, including ob/db and db/db mice, Zucker and ZDF rats, HF-fed rodents, and streptozotocin-induced diabetic rodents, exhibit elevations in glucocorticoids (14–17). Furthermore, adrenalectomy or glucocorticoid receptor (GR) antagonists ameliorate or in some cases prevent diabetes and obesity phenotypes (18,19). Accordingly, we hypothesized that antagonism or removal of the GIPR-dependent stimulation of corticosterone secretion after nutrient ingestion may contribute to one or more of the phenotypes exhibited by Gipr−/− mice. We now show that activation or disruption of the GIPR modulates glucocorticoid levels in mice, and GIP directly enhances glucocorticoid synthesis and secretion in adrenocortical cells. However, the reduction in glucocorticoid levels observed in Gipr−/− mice does not substantially contribute to the phenotypes of improved glucose tolerance and resistance to diet-induced obesity in HF-fed Gipr−/− mice.

**RESEARCH DESIGN AND METHODS**

All experiments were done using male mice acclimatized to handling before commencement of experiments. Wild-type C57BL/6 mice were obtained from the Toronto Centre for Phenogenomics (TCP, Toronto, ON, Canada). The generation and characterization of Gipr−/− mice has been described previously (20). Mice were housed under a 12-h light/dark cycle in the TCP animal facility.
facility with free access to standard rodent diet (2018, 18% kcal from fat; Harlan Teklad, Mississauga, ON, Canada) and water, except where otherwise noted. All procedures were conducted according to protocols and guidelines approved by the TCP Animal Care Committee.

**Acute stimulation by [D-Ala²]GIP (D-[Ala²]GIP)**. Overnight fasted C57BL/6 mice or ad libitum fed Gipr²⁻/⁻ and Gipr⁻⁻/⁻ mice were injected iperitoneally with 24 nmol/kg [D-Ala²]GIP (California Peptide Research Inc., Napa, CA) or saline. Blood for corticosterone was obtained from the tail vein.

**Ex viva ACTH sensitivity.** Adrenal glands from Gipr²⁻/⁻ and Gipr⁻⁻/⁻ mice were obtained after 5 weeks of HF diet, and responsiveness to ACTH was measured as described (21). Briefly, adrenals were excised, cleaned, halved, and incubated in vitro in Dulbecco's modified Eagle's medium with 25 mM/L HEPES and 0.1% w/v BSA. After preincubation for 120 min, the medium was changed and adrenals were incubated for 60 min to determine basal corticosterone production. Medium was changed again and 1 mM/L ACTH (Sigma-Aldrich, St. Louis, MO) was applied for 60 min. Medium was frozen for analysis of corticosterone levels.

**Basal corticosterone measurements.** Basal blood samples were obtained at the diurnal peak (1800 h) and trough (0900 h) of the corticosterone rhythm in Gipr²⁻/⁻ and Gipr⁻⁻/⁻ mice. Mice were in a quiet room for at least 1 h prior to sampling, and blood for corticosterone was obtained from the tail vein within 1 min of opening the cage.

**Stress experiments.** Gipr²⁻/⁻ and Gipr⁻⁻/⁻ mice were exposed to various stress regimens, including 24-h food deprivation, 30-min restraint stress, ACTH stimulation test (5 units/kg), and insulin-induced hypoglycemia (1.0 units/kg insulin, Humulin R, 100 units/mL; Lilly) after a 5-h fast. Blood was sampled from the tail vein, and blood glucose levels were measured using a Glucometer Elite blood glucose meter (Bayer, Toronto, ON, Canada). Basal plasma corticosterone samples were obtained from the tail vein of individually housed mice after 10 and 20 weeks of treatment at the diurnal peak (1900 h) and trough (0800 h) of the corticosterone rhythm. Mice were transported to the sampling room 3 h prior to the 1900 h sample to acclimatize and left in the room overnight for the 0800 h sample.

**RNA isolation.** Total RNA was extracted from adrenal glands, hypothalamus, brain, liver, and adipose tissue, or pituitary using the RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada). RNA from Y1 cells was extracted using Trizol (Molecular Research Center Inc., Cincinnati, OH).

**Statistical analysis.** All results are expressed as means ± SE. Statistical significance was assessed by ANOVA and where appropriate, a Student t-test using GraphPad Prism 4 (GraphPad Software, San Diego, CA). P < 0.05 was considered to be statistically significant.

**RESULTS**

The GIPR agonist [D-Ala²]GIP increases plasma corticosterone in mice via the GIPR. [D-Ala²]GIP administration to overnight fasted C57BL/6 mice induced a brisk rise in corticosterone levels (Fig. 1A); in contrast, no increase in plasma corticosterone levels occurred after [D-Ala²]GIP administration in Gipr⁻⁻/⁻ mice (Fig. 1B). To determine if chronic GIPR activation alters corticosterone levels, we assessed diabetic mice treated with saline or [D-Ala²]GIP twice daily for 60 days (26). Corticosterone levels were more than threefold higher in mice chronically injected with [D-Ala²]GIP (Fig. 1C).

**Basal corticosterone levels are reduced in Gipr⁻⁻/⁻ mice.** We next assessed plasma corticosterone in Gipr⁻⁻/⁻ mice. Basal corticosterone levels were reduced in Gipr⁻⁻/⁻ mice (Fig. 1D) during the peak of the circadian corticosterone rhythm at 1800 h, 1 h prior to their dark cycle. The lower corticosterone levels in Gipr⁻⁻/⁻ mice were not associated with simultaneous differences in glycemia (data not shown). We next examined the corticosterone response to stress in Gipr⁻⁻/⁻ mice. Plasma corticosterone responses to restraint stress or insulin-induced hypoglycemia were comparable across genotypes (Fig. 2). In a similar manner, exogenous administration of ACTH produced robust yet comparable increases in plasma corticosterone in Gipr²⁻/⁻ versus Gipr⁻⁻/⁻ mice (Fig. 2). In contrast, corticosterone levels were more than threefold higher in Gipr⁻⁻/⁻ mice after 24 h of food deprivation (Fig. 2). Glucose levels were
not different between Gipr<sup>+/+</sup> versus Gipr<sup>2/2</sup> mice during these experiments (data not shown). Corticosterone levels are reduced in HF-fed Gipr<sup>2/2</sup> mice in the absence of reduced hypothalamic–pituitary axis activation. HF feeding increases basal corticosterone levels (17). Accordingly, we examined whether the Gipr links excess nutrients to increased plasma corticosterone. Remarkably, basal corticosterone levels were reduced by 50% in Gipr<sup>2/2</sup> mice after 2 weeks of HF feeding (Fig. 3A). However, levels of plasma ACTH (Fig. 3A), pituitary proopiomelanocortin (pomc) (Fig. 3B), and hypothalamic corticotrophin-releasing hormone (crh) mRNA transcripts (Fig. 3C) were comparable in Gipr<sup>+/+</sup> versus Gipr<sup>2/2</sup> mice. GR expression also was similar in the pituitary, hypothalamus, and epididymal white adipose tissue of Gipr<sup>+/+</sup> versus Gipr<sup>2/2</sup> mice (Fig. 3B–D), and expression of the glucocorticoid synthesizing enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) was similar between genotypes (Fig. 3D). Hence, elimination of the Gipr is not associated with generalized perturbations in key molecular components of the hypothalamic–pituitary axis despite expression of Gipr mRNA at all levels of the HPA axis (Supplementary Fig. 1), nor is it associated with alterations in several genes regulating glucocorticoid synthesis and action in key target tissues.

Gipr<sup>2/2</sup> mice exhibit altered adrenal expression of steroidogenic genes and increased sensitivity to ACTH. To delineate mechanism(s) through which GIPR signaling controls corticosterone in mice, we assessed the expression of genes regulating adrenal steroidogenesis in Gipr<sup>+/+</sup> and Gipr<sup>2/2</sup> mice compared with wild-type littermates (n = 7–10). *P < 0.05, **P < 0.01 [D-Ala<sup>2</sup>]GIP vs. saline-injected control or Gipr<sup>2/2</sup> vs. Gipr<sup>+/+</sup>.
versus Gipr−/− mice after 2 weeks of HF feeding. Levels of StAR, cyp11A1, and dax1 mRNA transcripts were comparable in Gipr+/− mice, sfl mRNA transcripts were significantly reduced (P < 0.05), creb1 mRNA transcripts were increased (P = 0.07), and mc2r mRNA transcripts were significantly higher (P < 0.01) in Gipr+/− adrenals (Fig. 4A).

To assess whether increased levels of mRNA transcripts for the ACTH receptor (mc2r) reflected functionally increased sensitivity to ACTH, we administered a low dose of ACTH (1 nmol/L) to Gipr+/− and Gipr−/− mouse adrenals ex vivo. A significantly greater corticosterone response to ACTH was detected from Gipr−/− mouse adrenals, consistent with enhanced ACTH sensitivity (Fig. 4B).

**GIP regulates lipid accumulation in adrenocortical cells.** Because GIP enhances adrenal corticosterone secretion, we hypothesized that the Gipr regulates expression of genes controlling adrenal cholesterol homeostasis. Although the majority of mRNA transcripts encoding genes within the cholesterol biosynthetic and transport pathways were not differentially expressed in Gipr+/− versus Gipr+/− adrenal glands (Fig. 5A), expression of sr-b1 was significantly reduced in Gipr−/− adrenal glands (Fig. 5A).

Since SR-B1 is responsible for selective uptake of cholesterol esters from HDL, the primary source of adrenal cholesterol stores in mice (27,28), we examined levels of neutral lipids in adrenal glands of Gipr−/− mice using Oil Red O histochemistry. The intensity of Oil Red O staining in the adrenal cortex was clearly reduced after 9 weeks of a HF diet in Gipr−/− mice (Fig. 5B). Conversely, activation of the GIPR with [D-Ala2]GIP significantly increased incorporation of Oil Red O in Y1GIPR cells (Fig. 5C).

[D-Ala2]GIP directly stimulates steroidogenesis and increases expression of steroidogenic genes in Y1 cells. As native Y1 adrenocortical cells do not express an endogenous GIPR (Supplementary Fig. 1), we used Y1 mouse adrenocortical cells stably transfected with the rat GIPR cDNA. Y1GIPR cells exhibited a robust dose-dependent increase in cAMP levels in response to GIP (Fig. 6A). In a similar manner, ERK1/2 phosphorylation was rapidly increased after exposure to [D-Ala2]GIP (P < 0.05) (Fig. 6B). Because Y1 cells do not produce corticosterone (29), we assessed progesterone secretion in response to [D-Ala2]GIP. A fivefold increase in progesterone secretion was observed after treatment with [D-Ala2]GIP (P < 0.001) (Fig. 6C).

Steroidogenesis is under tight control by StAR, a protein that transports cholesterol from the outer to inner mitochondrial membrane to Cyp11A1, which cleaves the cholesterol side chain to initiate the rate-limiting step of corticosterone synthesis. Therefore, we assessed whether [D-Ala2]GIP regulates this pathway in Y1GIPR cells. [D-Ala2]GIP significantly increased StAR, cyp11A1, and sr-b1 mRNA transcript levels and increased sf-1 transcript levels (Fig. 6D). This stimulatory effect of [D-Ala2]GIP on gene expression was not significant for pp1a (cyclophilin), mc2r, ldr, or act7.

**Corticosterone supplementation does not exacerbate body weight gain in Gipr−/− mice.** To determine if lower corticosterone levels in Gipr−/− mice contribute to their
FIG. 5. GIP regulates lipid accumulation in adrenocortical cells. 
A: Expression of genes involved in adrenal cholesterol homeostasis was measured in adrenal glands from Gipr+/+ and Gipr−/− mice by real-time qRT-PCR after 2 weeks HF feeding (n = 8-9 per group). B: The intensity of Oil Red O staining for neutral lipids is reduced in adrenal glands from Gipr−/− mice compared with Gipr+/+ littermates after 9 weeks of HF feeding (n = 3 per group; original magnification ×10). C: Cortex; M, medulla. C: Elution of Oil Red O from Y1GIPR adrenocortical cells is increased after 7 days treatment with [D-Ala²]GIP (n = 3 per group). *P < 0.05 vs. Gipr+/+ mice, **P < 0.01 vs. saline control. (A high-quality digital representation of this figure is available in the online issue.)

metabolic phenotype, Gipr+/+ and Gipr−/− mice were supplemented with 5 μg/mL corticosterone in their drinking water and fed a HF diet for 22 weeks. Water and corticosterone intake were not affected by genotype (data not shown). Adrenal weights after 22 weeks were not different between vehicle-treated Gipr+/+ and Gipr−/− mice. However, adrenal weights (Fig. 7A) were significantly reduced in both genotypes as a result of corticosterone supplementation (P < 0.05), consistent with feedback inhibition of the HPA axis from exogenous corticosterone administration. Body weights increased over time with HF feeding (Fig. 7B), and Gipr−/− mice gained less weight than wild-type littermates. However, weight gain was not affected by corticosterone supplementation in Gipr+/+ versus Gipr−/− mice. Nocturnal food intake was slightly reduced in Gipr−/− mice (P < 0.02), as was ad libitum food intake (P = 0.02) (Supplementary Fig. 2), although this was no longer significant when normalized to body weight. Food intake was not altered by corticosterone supplementation. Locomotor activity was increased in Gipr−/− mice during the dark phase compared with Gipr+/+ mice; however, neither VO₂ nor locomotor activity was affected by corticosterone supplementation (Fig. 7C and D). Gipr−/− mice had reduced fat mass; however, corticosterone supplementation had no effect on fat (Fig. 7E) or lean mass (data not shown) in Gipr−/− mice.

Corticosterone supplementation does not impair glucose homeostasis in Gipr−/− mice. Overnight fasting glucose levels (~16-h fast) were not different between genotypes or affected by corticosterone supplementation (Fig. 8A and B). Corticosterone supplementation had no effect on oral or intraperitoneal glucose tolerance in Gipr+/+ or Gipr−/− mice (Fig. 8A and B). Despite comparable glucose levels, insulin levels (Fig. 8A and B) and insulin-to-glucose ratios (P < 0.05) (data not shown) to oral but not intraperitoneal glucose were reduced in Gipr−/− mice. Insulin sensitivity assessed by ITT was neither different between genotypes nor affected by corticosterone supplementation (Fig. 8C).

DISCUSSION

We have shown that activation of the GIPR increases plasma glucocorticoid levels in mice and that GIP directly activates steroidogenic gene expression in mouse adrenocortical cells. It seems likely that GIP also promotes steroidogenesis via increasing uptake of cholesterol since Gipr−/− mouse adrenal glands expressed lower levels of sr-b1 mRNA transcripts and had reduced neutral lipid staining, whereas Y1GIPR cells stimulated with [D-Ala²]GIP expressed higher transcript levels of sr-b1 and stored more neutral lipid. Since glucocorticoids are diabetogenic and obesigenic in rodents (16,18), we hypothesized that reduced glucocorticoid levels in Gipr−/− mice might contribute to their resistance to diet-induced obesity and preservation of insulin sensitivity and glucose tolerance observed after HF feeding. However, supplementation of drinking water with low-dose corticosterone did not alter energy balance, insulin sensitivity, or glucose tolerance in HF-fed Gipr−/− mice.

Pharmacological levels of GIP stimulate ACTH secretion from AtT20 mouse corticotrope cells (30), and the Gipr−/− is expressed in the hypothalamus and pituitary (11). Although Gipr−/− mice exhibited a twofold reduction in basal corticosterone levels, plasma ACTH, pituitary poma, and hypothalamic crh mRNA levels were not different.
Nevertheless, the increased adrenal expression of the ACTH receptor and enhanced adrenal sensitivity to ACTH in adrenal glands from Gipr<sup>2/2</sup> mice suggest the evolution of adaptive compensatory mechanisms that mask the impact of loss of adrenal GIP action. Enhanced ACTH sensitivity in Gipr<sup>2/2</sup> mice likely diminishes the extent of corticosterone deficiency and metabolic effects that might otherwise arise pursuant to elimination of GIPR action in the adrenal gland.

Further evidence for a direct effect of GIP on the adrenal gland was obtained in experiments using Y1GIPR cells. [D-Ala<sup>2</sup>]-GIP directly stimulated steroidogenesis, increased cAMP, activated the ERK pathway, and increased StAR, cyp11a1, sf-1, and sr-b1 gene expression. Conversely, mRNA levels of sf-1, a transcription factor critical for regulation of adrenal steroidogenesis (31), and levels of sr-b1, a downstream target of SF-1 (32), were reduced in adrenal glands from Gipr<sup>−/−</sup> mice. GIP likely mediates some of its effects on the adrenal gland via modifying cholesterol uptake and/or storage. Gipr<sup>−/−</sup> mice had less neutral lipid staining in the adrenal cortex after 9 weeks of HF feeding, whereas [D-Ala<sup>2</sup>]-GIP increased neutral lipid accumulation in Y1GIPR cells. Since sr-b1 mediates selective uptake of cholesterol from HDL, the most important pathway for adrenal cholesterol uptake in mice, and depletion of sr-b1 leads to deficits in corticosterone (28,33), it is likely that GIP mediates adrenal steroidogenesis in part via this cholesterol uptake pathway.

Although the corticosterone responses to restraint stress, insulin-induced hypoglycemia, and high-dose ACTH were normal in Gipr<sup>−/−</sup> mice, the more chronic stressor of 24-h food deprivation elicited a threefold greater corticosterone response in Gipr<sup>−/−</sup> mice. In contrast to potent stressors such as restraint and insulin, food deprivation does not significantly increase ACTH levels, but it does increase basal corticosterone levels by reducing hepatic glucocorticoid clearance (34,35). Hence, at the low ACTH levels associated with food deprivation, the greater adrenal sensitivity to ACTH in Gipr<sup>2/2</sup> mice may be unmasked, leading to differentially greater increases in corticosterone responses in Gipr<sup>−/−</sup> mice. In contrast, no differences in corticosterone levels are apparent under situations where ACTH levels would already be expected to be high, as exemplified by restraint and insulin. Thus, it is likely that food deprivation is associated with reduced hepatic clearance of corticosterone and enhanced sensitivity to ACTH.
lower levels of ACTH, leading to hypercorticosteronemia in Gipr<sup>−/−</sup> mice. Glucocorticoids regulate metabolism through stimulation of hepatic glucose production (36), impairment of insulin sensitivity and glucose tolerance (37), inhibition of insulin secretion (38), and facilitation of lipolysis (23). Chronic elevations of glucocorticoids promote fat deposition (23,39), insulin resistance (39), hepatosteatosis, hyperphagia, and decreased locomotion (39). Many commonly used rodent models of obesity or insulin resistance, including ob/ob and db/db mice, Zucker and ZDF rats, HF-fed rodents, and streptozocin-induced diabetic rodents, exhibit elevations in glucocorticoids (14–17). Adrenalectomy or administration of a glucocorticoid antagonist can ameliorate or in

some cases reverse the abnormal metabolic phenotype (18,19), illustrating the importance of glucocorticoids in the development of rodent obesity and diabetes. Administration of a peptide GIPR antagonist in HF-fed mice lowers corticosterone levels in association with reduced body weight and fat deposition, increased locomotion, and improved glucose homeostasis (7,8,40). However, our current data in HF-fed Gipr<sup>−/−</sup> mice suggest that modest reductions in plasma corticosterone do not appear to substantially
modify the dominant metabolic phenotypes arising after HF feeding in Gipr+/− mice.

Corticosterone supplementation did not significantly modify food intake, energy expenditure, weight gain, or fat mass in Gipr+/+ and Gipr−/− mice. However, corticosterone supplementation slightly improved oral but not intraperitoneal glucose tolerance in wild-type mice. This modest improvement was likely related to the small reductions in body weight and fat mass induced by corticosterone supplementation that would in turn improve glucose disposal. This reduction in fat mass may be related to the lipolytic effects of corticosterone at low concentrations (23). It is likely that the upregulation of ACTH sensitivity in Gipr−/− mice resulted in only a subtle reduction in plasma corticosterone that was not sufficient to lower weight gain or modify energy balance and glucose homeostasis. Consistent with our current data, Irwin et al. (7) demonstrated that administration of the GIP antagonist Pro3(GIP to ob/ob mice for 60 days significantly improved glucose control and insulin sensitivity, without concomitant changes in circulating corticosterone.

In summary, we show that GIP stimulates plasma glucocorticoid levels in mice and demonstrate that GIP directly activates steroidogenesis through stimulation of steroidogenic genes as well as srb1 expression and consequent adrenocortical lipid deposition. Gipr−/− mice compensate for disruption of GIP action in the adrenal gland via upregulation of mc2r expression and enhanced ACTH sensitivity. Corticosterone supplementation did not reverse the beneficial metabolic phenotype of HF-fed Gipr+/− mice, including resistance to diet-induced obesity and maintenance of oral glucose tolerance with lower levels of plasma insulin, implicating organs such as the brain and adipose tissue as potential mediators of the favorable Gipr+/− phenotype. Our findings may have relevance for envisioned therapeutic strategies using GIPR antagonists for the treatment of obesity and diabetes in human subjects. Because the GIP–adrenal axis does not appear to be functional in normal human subjects, the observation that manipulation of corticosterone levels does not substantially abrogate the beneficial metabolic phenotype of Gipr−/− mice has positive implications for targeting the GIPR in human subjects.

ACKNOWLEDGMENTS

H.E.B. has received fellowships from the Banting and Best Diabetes Centre and the Canadian Diabetes Association. J.E.C. has received fellowships from the Banting and Best Diabetes Centre and the Canadian Institutes of Health Research. J.R.U. has received fellowships from the Canadian Institutes of Health Research and the Alberta Heritage Foundation for Medical Research. A.M. has received a fellowship from the Canadian Institutes of Health Research. D.J.D. has received funding from the Canadian Institutes of Health Research (MOP 82700).

No potential conflicts of interest relevant to this article were reported.

H.E.B. was primarily responsible for the experimental design, experiments, interpretation, and writing of the manuscript. J.E.C., J.R.U., L.L.B., and A.M. contributed significantly to the experiments as well as data interpretation. D.J.D. contributed to the experimental design, interpretation of data, and writing of the manuscript and is the guarantor of the manuscript and takes responsibility for all aspects of the work.

The authors would like to thank Bernard Schimmer (University of Toronto) for kindly donating the Y1 mouse adrenocortical cell line and Carolyn Cummins (University of Toronto) for her helpful discussions.

REFERENCES

1. Vilsboell T, Kraupa T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–2713
2. Hamer H, Glätting G, Kaminska D, Pfleffer EP. Effects of gastric inhibitory polypeptide on plasma glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988;32:282–288
3. Oyen J, Morgan L, Fletcher J, Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267–272
4. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulino-metabolic phenotype of Gipr−/− mice. Our findings may have relevance for envisioned therapeutic strategies using GIPR antagonists for the treatment of obesity and diabetes in human subjects. Because the GIP–adrenal axis does not appear to be functional in normal human subjects, the observation that manipulation of corticosterone levels does not substantially abrogate the beneficial metabolic phenotype of Gipr−/− mice has positive implications for targeting the GIPR in human subjects.

REFERENCES

1. Vilsboell T, Kraupa T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–2713
2. Hamer H, Glätting G, Kaminska D, Pfleffer EP. Effects of gastric inhibitory polypeptide on plasma glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988;32:282–288
3. Oyen J, Morgan L, Fletcher J, Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267–272
4. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulino-metabolic phenotype of Gipr−/− mice. Our findings may have relevance for envisioned therapeutic strategies using GIPR antagonists for the treatment of obesity and diabetes in human subjects. Because the GIP–adrenal axis does not appear to be functional in normal human subjects, the observation that manipulation of corticosterone levels does not substantially abrogate the beneficial metabolic phenotype of Gipr−/− mice has positive implications for targeting the GIPR in human subjects.

REFERENCES

1. Vilsboell T, Kraupa T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–2713
2. Hamer H, Glätting G, Kaminska D, Pfleffer EP. Effects of gastric inhibitory polypeptide on plasma glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988;32:282–288
3. Oyen J, Morgan L, Fletcher J, Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267–272
4. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulino-metabolic phenotype of Gipr−/− mice. Our findings may have relevance for envisioned therapeutic strategies using GIPR antagonists for the treatment of obesity and diabetes in human subjects. Because the GIP–adrenal axis does not appear to be functional in normal human subjects, the observation that manipulation of corticosterone levels does not substantially abrogate the beneficial metabolic phenotype of Gipr−/− mice has positive implications for targeting the GIPR in human subjects.
21. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type I knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997;94:14024–14029

22. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004;127:546–558

23. Campbell JE, Peckett AJ, Dosouza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol 2011;300:C198–C209

24. Koehler JA, Drucker DJ. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 2006;55:1369–1379

25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–408

26. Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009;137:2146–2157

27. Temel RE, Trigatti B, DeMattos RB, Azhar S, Krieger M, Williams DL. Scavenger receptor class B type I (SR-BI) is the major route for the delivery of high density lipoprotein cholesterol to the steroidogenic pathway in cultured mouse adrenocortical cells. Proc Natl Acad Sci U S A 1997;94:13600–13605

28. Hoekstra M, Ye D, Hildebrand RB, et al. Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J Lipid Res 2009;50:1039–1046

29. Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol Cell Endocrinol 2004;228:23–38

30. Westendorf JM, Schonbrunn A. Peptide specificity for stimulation of corticotropin secretion: activation of overlapping pathways by the vasoactive intestinal peptide family and corticotropin-releasing factor. Endocrinology 1985;116:2528–2535

31. Parker KL, Rice DA, Lala DS, et al. Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res 2002;57:19–36

32. Cao G, Garcia CK, Wynne KL, Schultz RA, Parker KL, Hobbs HH. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J Biol Chem 1997;272:33068–33076

33. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuizen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008;118:364–375

34. Kiss A, Jezova D, Aguilera G. Activity of the hypothalamic pituitary adrenal axis and sympathoadrenal system during food and water deprivation in the rat. Brain Res 1994;663:84–92

35. Woodward CJ, Hervey GR, Oakey RE, Whitaker EM. The effects of fasting on plasma corticosterone kinetics in rats. Br J Nutr 1991;66:117–127

36. Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW. Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J Biol Chem 1993;268:12952–12957

37. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabeticogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 1992;89:6035–6039

38. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997:99:414–423

39. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McGowan BS. Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 2010;151:2117–2127

40. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007;50:1762–1762